University of Ottawa Heart Institute Biobank of Human Samples for Research , Canada

Certification Status: Approved

Registration Status: Completed

Objective: The major purpose of this project is to develop a large biobank of de-identified blood, DNA and tissue samples that will be available for researchers studying cardiovascular disease. The goals are to obtain new information on â€œbiomarkersâ€, including blood proteins and lipids, genetic variations in DNA (deoxyribonucleic acid), RNA (ribonucleic acid) expression, that predispose to cardiovascular disease and/or its risk factors including dyslipidemia, obesity, diabetes mellitus and hypertension. Some of these biomarkers may also aid in the diagnosis of disease or in determining disease progression or in identifying the optimal treatment for different individuals.

Registered Biobank Name	University of Ottawa Heart Institute Biobank of Human Samples for Research
Biobank Leader	Biobank manager: Susan McClinton
Country	Canada
Email for biobank inquiries	smcclinton@ottawaheart.ca
Principal Investigator	Dr. Ruth McPherson
Website
User Type Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper	Poly - Collection aimed at supporting undetermined, multiple users with ethics approved research projects, through a defined access/application mechanism.

Biospecimen Collected:

Cohort Highlights

100 cases Next Generation Sequencing assay to detect all classes of genetic variant in Lung Cancer using a single Diagnostic test.
200 cases Colorectal TMA for QC purposes in support of study of tumor infiltrating lymphocytes in ovarian cancer tissues.
Build 300 cases breast cancer TMA containing primary tumour and matched metastatic LN for various subtypes (luminal, HER2, Triple negative). Start with Triple negatives.
125 cases Breast tumour and metastatic lymph nodes in breast cancer cases with outcomes of metastasis to lung or bone.
100 cases of rare tumours - fibrolamellar hepatocellular carcinoma. FFPE, frozen, BC.
200 cases of FFPE tissue sections from breast, lung adenocarcinoma, and lung squamous cell carcinoma with matching normal tissue (only pathology data requested).